Immunovant’s Batoclimab Excels in Clinical Trials for Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
The pivotal Phase III study in myasthenia gravis met its primary endpoint with meaningful improvements in MG-ADL across both higher and lower dose arms.
Image Credit: Adobe Stock Images/Lila Patel
Immunovant has shared positive results of its batoclimab in a Phase III clinical trial in myasthenia gravis (MG) and a Phase IIb trial in chronic inflammatory demyelinating polyneuropathy (CIDP).1
In the Phase III MG study, batoclimab demonstrated a meaningful change from baseline in Myasthenia Gravis Activities of Daily Living (MG-ADL) in AChR+ population at week 12, with a 5.6 point improvement in the higher dose arm and a 4.7 point improvement in the lower dose arm, meeting the primary endpoint.
Results from the Phase IIb trial in CIDP were from Period 1 following a standard of care washout. Data from the study show a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in patients who achieved an IgG lowering greater than 70%.
In a press release, Pete Salzmann, MD, chief executive officer of Immunovant, said: “We are excited to share positive results from our MG and CIDP studies. While neurologists and patients are very enthusiastic about currently approved FcRn inhibitors, they tell us that they also see a lot of potential for a next-generation FcRn inhibitor that can offer deeper and more durable responses for patients whose disease is still affecting their daily function.”
While results across both studies were positive, Immunovant stated it does not intend to seek regulatory approval for batoclimab in MG or CIDP. The company will wait to make a final decision on regulatory submissions for batolclimab until it receives results from Phase III studies evaluating the therapy in thyroid eye disease.
Salzmann continued: “Today’s results show that deeper IgG reduction leads to deeper responses in MG and CIDP. Beyond the results in MG and CIDP, we believe that our core thesis - that deeper IgG reduction, at the levels achieved by high dose batoclimab and high dose IMVT-1402, leads to improved clinical outcomes - will apply to a wide range of auto-antibody mediated conditions.”
Immunovant also announced it has received clearance for its Investigational New Drug (IND) applications for its lead asset, IMVT-1402, in both MG and CIDP. The company will look to advance its IMVT-1402 program using data gathered from the batoclimab studies.
Reference
1. Immunovant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies. News release. Immunovant. March 19, 2025. Accessed March 19, 2025. https://www.immunovant.com/investors/news-events/press-releases/detail/71/immunovant-announces-positive-results-for-batoclimab
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
